Predicine and Kintor Pharma today announced that new data on Proxalutamide (GT0918) in a Phase I/II clinical trial (NCT02826772) will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. Metastatic castration resistant prostate cancer (mCRPC) is a complex disease with distinct molecular features in relation to genomic instability and...